Contact
Please use this form to send email to PR contact of this press release:
Cellectar Receives FDA Fast Track Designation for CLR 131 in Relapsed or Refractory Multiple Myeloma
TO:
Please use this form to send email to PR contact of this press release:
Cellectar Receives FDA Fast Track Designation for CLR 131 in Relapsed or Refractory Multiple Myeloma
TO: